Risks in clinical applications of oseltamivir phosphate in the real world.

Abstract

A retrospective analysis was conducted on the use of oseltamivir phosphate in outpatients and inpatients in our hospital from February 2016 to February 2019. The indications, purposes, dosage, combination, and adverse reactions were analysed focussing on the rationality and safety of oseltamivir. The relationship between adverse reactions and age, allergic history, underlying diseases, and combined drug use were analysed to find the risk factors associated therewith. A total of 1795 adult patients and 3199 children were treated with oseltamivir phosphate. In the adult group 1481 patients (82.5%) and in the child group, 2602 patients (81.3%) received oseltamivir for therapeutic ourposes. The main clinical diagnoses were upper respiratory tract infection, bronchitis, and pneumonia. Only 767 cases (15.2%) were confirmed as influenza virus infection by virological examination, the rest were suspected influenza cases and clinically diagnosed influenza cases. For preventive drug use, an adult group comprising 314 cases (17.5%) and a child group with 597 cases (18.7%) were identified. The dosage and course of treatment were more standardised, but there were too many types of combined drugs, and the indications of preventive use were insufficient in some cases. A total of 106 adverse drug reactions (2.12%) was recorded, mainly affecting the digestive system and neuropsychiatric systems. The rate of adverse drug reactions was related to age and the number of drug combinations. Attention should also be paid to age, combination of drugs, and allergy history.